drugset / Trial / NCT02804373

Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome

NCT02804373

Phase 2/3 Completed 50 enrolled University Hospital, Toulouse
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The investigator thinks that the oxytocin (OT) can improve durably and significantly the behavior disorders and thus the socialization but also the satisfaction and could thus be an interesting therapeutic alternative for the patients presenting a Prader-Willi Syndrome (SPW). Although today several studies demonstrated the effects of the OT in various domains of the behavior, the investigator do not know either its specificity of action about the cerebral level, or its duration of action, or the optimal modalities of administration and in particular at patients SPW.

Timeline

Start
2014-06
Primary completion
2019-01
Completion
2019-06-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxytocin Peptide 24 iu Intranasal

Indications